close
Add to watchlist
Adolor Corp (ADLR) Healthcare, Biotechnology & Drugs
Adolor Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of prescription pain management products. Its product includes ENTEREG (alvimopan), a small molecule peripherally-acting mu-opioid receptor antagonist designed to block the adverse side effects of opioid analgesics on the gastrointestinal tract, as well as for the management of postoperative ileus following bowel resection surgery that causes significant discomfort for patients. The company's product candidates in various stages of clinical and preclinical development include two novel delta opioid receptor agonists that are in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; a mu opioid receptor antagonist entering development for chronic OBD; and various opioid and non-opioid discovery programs. Adolor Corporation was founded in 1993 and is headquartered in Exton, Pennsylvania.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 4.77 |
| Volume | 0 |
| Volume Avg | 679697 |
| 52 Week High | 4.83 |
| 52 Week Low | 1.09 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.07 |
| EPS change Q/Q | -128.57% |
| EPS change Q/Q Yr ago | -23.81% |
| EPS change Q/Q next Q est | -14.29% |
| EPS change Y/Y | -77.78% |
| REV change Q/Q | -18.18% |
| REV change Q/Q Yr ago | -15.89% |
| EPS next Q est | -0.14 |
| EPS next Y est | -0.69 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |